Biologics Market

Biologics Market by Sources (Microbial, Mammalian, and Others), Products (MABs [Applications {Diagnostic (Biochemical Analysis and Diagnostic Imaging), Therapeutic (Direct MAB Agents and Targeting MAB Agents), Protein Purification, and Others} and Types {Murine, Chimeric, Humanized, Human, and Others}], Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others), Diseases (Oncology [Products {MABs, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others}], Infectious Diseases [Products {MABs, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others}], Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced and In-house), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2301
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 164
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global biologics market size is estimated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the advancement in the research activities & diagnostics, high number of product approvals, and great prevalence of diseases worldwide.

Biologics Market key takeaways

Biologics are genetically engineered proteins, which are derivative of human genes. As per the US Food and Drug Administration (FDA), biologics can be prepared from proteins, sugars, or maybe living entities such as cells and tissues, nucleic acids or complex combinations of these substances. The majority of biologics are complex combinations that are not easy to identified or characterize and are susceptible to microbial infections as well as heat sensitive. The biologic products are obtained from several natural sources such as humans, microorganisms, or animals. These products comprise of allergenic, vaccines, somatic cells, blood and blood components, tissues, gene therapy, and recombinant therapeutic proteins. The advanced and complex biotechnology techniques are used to manufacture biologics. Different products of biologics are vaccines, monoclonal antibodies, recombinant hormones/proteins, cellular-based biologics, gene-based biologics, and others. Applications of the biologics are cancer, autoimmune diseases, rare diseases, infectious diseases, and others.

As per the reports of 2018 by the World Health Organization (WHO), chronic diseases was responsible for more than 41 million people death every year globally. Cardiovascular diseases is responsible for high number of chronic disease deaths that is 17.9 million people yearly, which is led by cancers with 9 million, respiratory diseases with 3.9 million death, and diabetes is with 1.6 million deaths. These four diseases are responsible for around 80% of all chronic disorder related deaths. Physical inactivity, tobacco use, unhealthy diets, and alcohol consumption are some of them major factors for increasing the risk of mortality from non-communicable diseases.? In addition, the growing geriatric population is much at risk to chronic diseases, which supports the growth of the biologics market.

The COVID-19 pandemic outbreak proved to be beneficial for the biologics market since there has been a great demand for biologics due to the pandemic. For example, the collaboration of China-based CanSino Biologics and National Research Council of Canada in May 2020, for the clinical development of a COVID-19 vaccine in Canada, has boosted the market for more research activities of the COVID-19 vaccines. This collaboration was focused on the development of vaccine, called as Ad5-nCoV, which is an adenovirus type 5 vector-based vaccine. Thus, this shows that wide research and development activities on biologics for the prevention and treatment of COVID-19 are taking place around the world.

Market Trends, Drivers, Restraints, and Opportunities

  • Advancements in the manufacturing capabilities of the companies for biological products are estimated to push the biopharmaceutical production capacity. This is a major driver of the biologics market.
  • Rising interest of pharmaceutical firms towards massive development of biologics and increasing investments of the companies are propelling the market growth.
  • High research and development activities in the field and strong pipeline of products are projected to support the market growth in the coming years.
  • Biologics are extremely susceptible to light, heat conditions, and need proper refrigeration, which results in non-consistent quality available around the globe. This is proving to be a key restraining factor of the market growth.
  • High disease prevalence, increased focus of major players on biologics as well as governments’ initiatives, and extensive research activities are creating huge opportunities of the market expansion during the forecast period.

Scope of the Report

The report on the global biologics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Biologics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Sources (Microbial, Mammalian, and Others), Products (MABs [Applications {Diagnostic (Biochemical Analysis and Diagnostic Imaging), Therapeutic (Direct MAB Agents and Targeting MAB Agents), Protein Purification, and Others} and Types {Murine, Chimeric, Humanized, Human, and Others}], Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others), Diseases (Oncology [Products {MABs, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others}], Infectious Diseases [Products {MABs, Vaccines, Recombinant Proteins, Antisense, RNAi, & Molecular Therapy, and Others}], Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), and Manufacturing (Outsourced and In-house)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Abbvie Inc.; Amgen Inc.; Eli Lilly & Company; Pfizer Inc.; Samsung Biologics; Sanofi; Merck & Co. Inc.; F Hoffman La Roche; Celltrion; and Addgene.

 

Market Segment Insights

Microbial segment is expected to grow at a rapid pace

Based on sources, the global biologics market is divided into microbial, mammalian, and others. The microbial segment is expected to grow at a rapid pace in the coming years due to the high number of drugs developed by the use of microbial products. Escherichia Coli and yeast are the most used microbes in this segment. Products manufactured through these systems are granulocyte-macrophage colony-stimulating factor, platelet-derived growth factor, recombinant insulin, and recombinant interferon.

Meanwhile, the mammalian segment is expected to register at a fast growth pace in the coming years due to the high demand for mammals in the development of biologics product. Moreover, the rising research and development activities in the segment is projected to drive the overall market growth during the forecast period.

Biologics Market  by sources

Monoclonal antibodies segment is projected to expand at a considerable CAGR

On the basis of products, the market is divided into monoclonal antibodies (MABs), vaccines, recombinant proteins, antisense, RNAi, & molecular therapy, and others. The MABs segment is further classified on the basis of application and types. The application segment includes diagnostics, therapeutics, protein purification, and others; while the diagnostics segment consists of biochemical analysis and diagnostic imaging. The therapeutics segment is further bifurcated into direct MAB agents and targeting MAB agents. On the basis of types, it is divided into murine, chimeric, humanized, human, and others.

The monoclonal antibodies segment is projected to expand at a considerable CAGR during the forecast period attributed to the high use of drugs in several areas for disease therapeutics. MABs works on unhealthy cells without causing troubles to healthy body cells. These drugs are used in treatment of autoimmune diseases, cancer management, and rheumatoid arthritis. Meanwhile, the vaccines segment is anticipated to grow substantially in the near future due to high investments, extensive R&D activities, and increasing demand for vaccines.

Oncology segment is estimated to hold a major share of the market

Based on diseases, the global biologics market is segregated into oncology, infectious diseases, immunological disorders, cardiovascular disorders, haematological disorders, and others. The oncology segment is estimated to hold a major share of the market during the projected period as the growing prevalence of cancer cases along with high research in the segment. Extensive research is carried out on the antisense therapies and gene therapies for cancer treatment, which is likely to propel the segment growth in the coming years.

In-house manufacturing segment is anticipated to grow at substantial rate

On the basis of manufacturing, the market is bifurcated in to in-house and outsourced. The in-house manufacturing segment is anticipated to grow at substantial rate of the market during the targeted period due to the rising preference of companies to manufacture the products rather than outsourcing it. The companies are investing heavily in the segment and increasing their manufacturing capacity. These factors are helping the segment growth at significant rate but the outsourcing segment is experiencing a moderate growth rate.

Biologics Market by manufacturing

North America is anticipated to constitute a major market share

In terms of regions, the global biologics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major market share during the forecast period. The regional market growth is attributed to high incidences of chronic diseases, high population with alcohol and smoking habits, and rising aging population in the region. The region also has well-developed healthcare services as well as high quality research in the field of biologics, which is expected to fuel the further development of the regional market. Highly skilled professionals and technologically advanced equipment are key factors driving the market growth in the region.

Meanwhile, Asia Pacific is a key market destination that hold tremendous opportunities to grow in the coming future as there is high number of the targeted patients. Additionally, large number of research projects and heavy investments are projected to boost the market growth in the region.

Segments

Segments Covered in the Report
The global biologics market has been segmented on the basis of

Sources

  • Microbial
  • Mammalian
  • Others

Products

  • MABs
    • Applications
      • Diagnostic
        • Biochemical Analysis
        • Diagnostic Imaging
      • Therapeutic
        • Direct MAB Agents
        • Targeting MAB Agents
      • Protein Purification
      • Others
    • Types
      • Murine
      • Chimeric
      • Humanized
      • Human
      • Others
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

Diseases

  • Oncology
    • Products
      • MABs
      • Vaccines
      • Recombinant Proteins
      • Antisense, RNAi, & Molecular Therapy
      • Others
  • Infectious Diseases
    • Products
      • MABs
      • Vaccines
      • Recombinant Proteins
      • Antisense, RNAi, & Molecular Therapy
      • Others
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Manufacturing

  • Outsourced
  • In-house

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Abbvie Inc.
  • Amgen Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Samsung Biologics
  • Sanofi Merck & Co. Inc.
  • F Hoffman La Roche
  • Celltrion
  • Addgene

Competitive Landscape

Key players competing in the global biologics market are Sanofi; Abbvie Inc.; Eli Lilly & Company; Pfizer Inc.; Samsung Biologics; Merck & Co. Inc.; Amgen Inc.; F Hoffman La Roche; Celltrion; and Addgene. These major players are actively engaged in various business development strategies such as mergers, collaborations, and partnership along with launching new products and expansion of production capacity to enhance their market positions.

Biologics Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biologics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Biologics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Biologics Market - Supply Chain
  4.5. Global Biologics Market Forecast
     4.5.1. Biologics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Biologics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Biologics Market Absolute $ Opportunity
5. Global Biologics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Biologics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Biologics Demand Share Forecast, 2019-2026
6. North America Biologics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Biologics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Biologics Demand Share Forecast, 2019-2026
7. Latin America Biologics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Biologics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Biologics Demand Share Forecast, 2019-2026
8. Europe Biologics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Biologics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Biologics Demand Share Forecast, 2019-2026
9. Asia Pacific Biologics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Biologics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Biologics Demand Share Forecast, 2019-2026
10. Middle East & Africa Biologics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Biologics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Biologics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Biologics Market: Market Share Analysis
  11.2. Biologics Distributors and Customers
  11.3. Biologics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Abbvie Inc.
     11.4.2. Amgen Inc.
     11.4.3. Eli Lilly & Company
     11.4.4. Pfizer Inc.
     11.4.5. Samsung Biologics

Segments Covered in the Report
The global biologics market has been segmented on the basis of

Sources

  • Microbial
  • Mammalian
  • Others

Products

  • MABs
    • Applications
      • Diagnostic
        • Biochemical Analysis
        • Diagnostic Imaging
      • Therapeutic
        • Direct MAB Agents
        • Targeting MAB Agents
      • Protein Purification
      • Others
    • Types
      • Murine
      • Chimeric
      • Humanized
      • Human
      • Others
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

Diseases

  • Oncology
    • Products
      • MABs
      • Vaccines
      • Recombinant Proteins
      • Antisense, RNAi, & Molecular Therapy
      • Others
  • Infectious Diseases
    • Products
      • MABs
      • Vaccines
      • Recombinant Proteins
      • Antisense, RNAi, & Molecular Therapy
      • Others
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Manufacturing

  • Outsourced
  • In-house

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Abbvie Inc.
  • Amgen Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Samsung Biologics
  • Sanofi Merck & Co. Inc.
  • F Hoffman La Roche
  • Celltrion
  • Addgene

Key players competing in the global biologics market are Sanofi; Abbvie Inc.; Eli Lilly & Company; Pfizer Inc.; Samsung Biologics; Merck & Co. Inc.; Amgen Inc.; F Hoffman La Roche; Celltrion; and Addgene. These major players are actively engaged in various business development strategies such as mergers, collaborations, and partnership along with launching new products and expansion of production capacity to enhance their market positions.

Biologics Market by key players

Buy Report